Regular Article CLINICAL TRIALS AND OBSERVATIONS Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
نویسندگان
چکیده
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study David M. Ross, Susan Branford, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, David T. Yeung, Phuong Dang, Jarrad M. Goyne, Cassandra Slader, Robin J. Filshie, Anthony K. Mills, Junia V. Melo, Deborah L. White, Andrew P. Grigg, and Timothy P. Hughes
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML Susan Branford, David T. Yeung, David M. Ross, Jodi A. Prime, Chani R. Field, Haley K. Altamura, Alexandra L. Yeoman, Jasmina Georgievski, Bronte A. Jamison, Stuart Phillis, Brad Sullivan, Nancy E. Briggs, Mark Hertzberg, John F. Seymour, John Rey...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-
Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronicphase CML after failure on interferonwere treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 mon...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early molecular response to posttransplantation imatinib determines outcome in MRD Philadelphia-positive acute lymphoblastic leukemia (Ph ALL)
In adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph ALL), minimal residual disease (MRD) after stem cell transplantation (SCT) is associated with a relapse probability exceeding 90%. Starting imatinib in the setting of MRD may decrease this high relapse rate. In this prospective multicenter study, 27 Ph ALL patients received imatinib upon detection of MRD after SCT. Bcr-a...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
The BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) has shown remarkable efficacy in the treatment of chronic myelogenous leukemia (CML), with a high proportion of patients achieving complete cytogenetic responses (CCRs). However, it is not clear whether remissions will be durable and whether imatinib mesylate can eliminate the malignant primi...
متن کاملResistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem.
The majority of patients with chronic phase chronic myeloid leukaemia (CP-CML) treated with imatinib achieves cytogenetic disease remission. Molecular monitoring for residual disease has prognostic significance: rising BCR-ABL levels may provide earliest indication that a patient has become resistant to treatment. The emergence of resistance to imatinib has dampened the enthusiasm for this drug...
متن کامل